Review of the Fibrinolytic System: Comparison of Different Antifibrinolytics used During Cardiopulmonary Bypass

Author(s): Caroline Van Aelbrouck, Lars Englberger, David Faraoni.

Journal Name: Recent Patents on Cardiovascular Drug Discovery (Discontinued)

Volume 7 , Issue 3 , 2012


Antifibrinolytic agents are often used in different clinical situations, especially in cardiac surgery. During several years, aprotinin was the drug of choice because more than antifibrinolytic properties, aprotinin offers a direct effect on kallikrein and inflammatory pathways. In 2008, The Blood Conservation Using Antifibrinolytics in a Randomized Trial (BART) initiated a discussion about real risks associated with aprotinin administration. Tranexamic acid and epsilon- aminocaproic acid appear to be interesting alternatives in our daily practice. The exact mechanism of action, the pharmacokinetic parameters, the efficacy, and the safety profile need to be clarified for lysine analogs. In this review, the different antifibrinolytics will be described with a special interest into the route of work, and recent patents. Current studies about the pharmacokinetic and the pharmacodynamic profile will be described, and finally the benefit-to-risk balance in patients undergoing cardiac surgery with cardiopulmonary bypass will be discussed.

Keywords: Antifibrinolytics, aprotinin, epsilon-aminocaproic acid, fibrinolysis, tranexamic acid

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2012
Page: [175 - 179]
Pages: 5
DOI: 10.2174/157489012803832793
Price: $100

Article Metrics

PDF: 24